Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

HIV-1 replicative fitness in elite controllers.

Lobritz MA, Lassen KG, Arts EJ.

Curr Opin HIV AIDS. 2011 May;6(3):214-20. doi: 10.1097/COH.0b013e3283454cf5. Review.

PMID:
21430530
2.

HLA-B*57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice.

Salgado M, Swanson MD, Pohlmeyer CW, Buckheit RW 3rd, Wu J, Archin NM, Williams TM, Margolis DM, Siliciano RF, Garcia JV, Blankson JN.

J Virol. 2014 Mar;88(6):3340-52. doi: 10.1128/JVI.03380-13. Epub 2014 Jan 3.

3.

Effective downregulation of HLA-A*2 and HLA-B*57 by primary human immunodeficiency virus type 1 isolates cultured from elite suppressors.

Nou E, Zhou Y, Nou DD, Blankson JN.

J Virol. 2009 Jul;83(13):6941-6. doi: 10.1128/JVI.00306-09. Epub 2009 Apr 22.

4.

The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M.

J Virol. 2003 Jun;77(12):6889-98.

5.

The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control.

Zaunders J, Dyer WB, Churchill M.

Curr Opin HIV AIDS. 2011 May;6(3):151-6. doi: 10.1097/COH.0b013e3283454d5b. Review.

PMID:
21378562
6.

Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101.

Kawashima Y, Kuse N, Gatanaga H, Naruto T, Fujiwara M, Dohki S, Akahoshi T, Maenaka K, Goulder P, Oka S, Takiguchi M.

J Virol. 2010 Jul;84(14):7151-60. doi: 10.1128/JVI.00171-10. Epub 2010 Apr 21.

7.

Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN.

J Virol. 2010 Jul;84(14):7018-28. doi: 10.1128/JVI.00548-10. Epub 2010 May 5.

8.

[HIV controllers: how these patients control viral replication?].

Lambotte O.

Med Sci (Paris). 2012 Feb;28(2):172-8. doi: 10.1051/medsci/2012282015. Epub 2012 Feb 27. Review. French.

9.

Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.

Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, Markle TJ, Martin E, Block BL, Trocha A, Kadie CM, Allen TM, Pereyra F, Heckerman D, Walker BD, Brockman MA.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):100-8. doi: 10.1097/QAI.0b013e3181fe9450.

10.

HIV-1 elite controllers: beware of super-infections.

Clerc O, Colombo S, Yerly S, Telenti A, Cavassini M.

J Clin Virol. 2010 Apr;47(4):376-8. doi: 10.1016/j.jcv.2010.01.013. Epub 2010 Feb 13.

PMID:
20153976
11.

Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Lai JI, Licht AF, Dugast AS, Suscovich T, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME.

J Virol. 2014 Mar;88(5):2799-809. doi: 10.1128/JVI.03130-13. Epub 2013 Dec 18.

12.

HLA B*5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells.

Mendoza D, Royce C, Ruff LE, Ambrozak DR, Quigley MF, Dang T, Venturi V, Price DA, Douek DC, Migueles SA, Connors M.

J Virol. 2012 Apr;86(7):4014-8. doi: 10.1128/JVI.06982-11. Epub 2012 Jan 25.

13.

Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?

Blankson JN.

Antiviral Res. 2010 Jan;85(1):295-302. doi: 10.1016/j.antiviral.2009.08.007. Epub 2009 Sep 4. Review.

14.

How do HIV elite controllers do what they do?

Saag M, Deeks SG.

Clin Infect Dis. 2010 Jul 15;51(2):239-41. doi: 10.1086/653678. No abstract available.

15.

High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.

Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Delfraissy JF, Saez-Cirion A, Ferrari G.

PLoS One. 2013 Sep 23;8(9):e74855. doi: 10.1371/journal.pone.0074855. eCollection 2013.

16.

HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication.

Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF; SEROCO-HEMOCO Study Group.

Clin Infect Dis. 2005 Oct 1;41(7):1053-6. Epub 2005 Aug 30. Erratum in: Clin Infect Dis. 2005 Dec 1;41(11):1694. Clin Infect Dis. 2005 Sep 15;41 Suppl 6:1694.

17.

CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.

Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M.

J Clin Invest. 2011 Apr;121(4):1549-60. doi: 10.1172/JCI44539. Epub 2011 Mar 14.

18.

Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study).

Lamine A, Caumont-Sarcos A, Chaix ML, Saez-Cirion A, Rouzioux C, Delfraissy JF, Pancino G, Lambotte O.

AIDS. 2007 May 11;21(8):1043-5.

PMID:
17457100
19.

Learning from the elite.

Trivedi B.

Nature. 2010 Jul 15;466(7304):S4. doi: 10.1038/nature09235. No abstract available.

PMID:
20631703
20.

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ.

Nature. 2004 Dec 9;432(7018):769-75.

PMID:
15592417
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk